10.11.17
Schreiner MediPharm recently implemented a special “Late Stage Customization” service in partnership with its customer, Biotest AG. The new process allows for faster production of functional labels on short demand.
As a result, Biotest benefits from greater flexibility and is able to respond to market requirements with agility, while Schreiner MediPharm assists its customer in meeting the demands of current segmentation trends in the pharmaceutical industry.
Biotest is a global supplier of plasma proteins and biotherapeutic drugs primarily used in clinical immunology, hematology and intensive care medicine. Due to its growth, an increasing and diversified product pipeline and complex market conditions, Biotest is seeking a variable supply chain in which speed-to-market and focus on patient needs play an important part.
To address these challenges, Biotest is utilizing Schreiner MediPharm’s special Late Stage Customization service. A process center specifically dedicated to this purpose ensures optimum workflow, meeting the exacting quality requirements of the pharmaceutical industry. The labels are pre-produced in large quantities and warehoused at Schreiner MediPharm’s facility as semi-finished goods. As requested by Biotest, the pre-produced labels are customized by digital printing and delivered on short notice.
“We benefit from a high level of customization, short lead times, fast delivery and high flexibility for short-term demand,” said Stefan Sadkowiak, head of final packaging at Biotest. “In addition, our process costs have decreased. We no longer have to comply with minimum ordering quantities, have reduced our warehousing expense and avoid destruction costs of preprinted labels due to text revisions.”
As a result, Biotest benefits from greater flexibility and is able to respond to market requirements with agility, while Schreiner MediPharm assists its customer in meeting the demands of current segmentation trends in the pharmaceutical industry.
Biotest is a global supplier of plasma proteins and biotherapeutic drugs primarily used in clinical immunology, hematology and intensive care medicine. Due to its growth, an increasing and diversified product pipeline and complex market conditions, Biotest is seeking a variable supply chain in which speed-to-market and focus on patient needs play an important part.
To address these challenges, Biotest is utilizing Schreiner MediPharm’s special Late Stage Customization service. A process center specifically dedicated to this purpose ensures optimum workflow, meeting the exacting quality requirements of the pharmaceutical industry. The labels are pre-produced in large quantities and warehoused at Schreiner MediPharm’s facility as semi-finished goods. As requested by Biotest, the pre-produced labels are customized by digital printing and delivered on short notice.
“We benefit from a high level of customization, short lead times, fast delivery and high flexibility for short-term demand,” said Stefan Sadkowiak, head of final packaging at Biotest. “In addition, our process costs have decreased. We no longer have to comply with minimum ordering quantities, have reduced our warehousing expense and avoid destruction costs of preprinted labels due to text revisions.”
